Clinical Trials Logo

Filter by:
NCT ID: NCT05037812 Active, not recruiting - Clinical trials for Tibial Plateau Fractures

Role of Multimodal Analgesia in Decreasing Perioperative Pain in Tibial Plateau Fractures

Start date: March 25, 2019
Phase: Early Phase 1
Study type: Interventional

The investigators goal of the proposed research study is to determine the effectiveness of periarticular multimodal analgesia in the setting of tibial plateau fractures. Effectiveness of the multimodal analgesia is defined as lower pain scores.

NCT ID: NCT05037149 Active, not recruiting - Solid Tumor Clinical Trials

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Start date: November 1, 2021
Phase: Phase 1
Study type: Interventional

An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.

NCT ID: NCT05036330 Active, not recruiting - Clinical trials for Malignant Head and Neck Neoplasm

ProvoxLife Adoption Trends for Heat-Moisture Exchanger

Start date: May 21, 2021
Phase:
Study type: Observational

This study examines factors that affect how often patients who have a total laryngectomy use a ProvoxLife heat-moisture exchanger (HME) system to help improve their lung function. ProvoxLife HMEs are single use heat- and moisture exchangers for patients breathing through a tracheostoma. Information from this study may help doctors learn more about factors associated with patterns of use and how often patients use the ProvoxLife HME system.

NCT ID: NCT05036135 Active, not recruiting - Clinical trials for Pulmonary Arterial Hypertension

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

IMPAHCT
Start date: December 2, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension (PAH). The Phase 2b part of the study will assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase 2b primary endpoint will be the placebo corrected change in pulmonary vascular resistance (PVR). The Phase 3 primary endpoint will be the placebo corrected change in 6-minute walk distance (6MWD) after 24 weeks of treatment.

NCT ID: NCT05035940 Active, not recruiting - Noise Exposure Clinical Trials

Federal Aviation Administration (FAA) National Sleep Study

NSS
Start date: September 7, 2021
Phase:
Study type: Observational

This observational study will examine the relationship between aircraft noise exposure in the bedroom and objectively assessed sleep disturbance. Surveys will be mailed to randomly selected households around selected airports to recruit individuals for a 5 night in-home sleep study. Eligible survey respondents interested in participating in the sleep study will record nighttime indoor sounds using a portable audio recorder and wear a small device that collects heart rate and movement data for 5 consecutive nights. They will also complete brief morning questionnaires about their previous night's sleep and their sleep quality and a participant characteristics questionnaire. Collected data will be used to create an exposure-response model between aircraft noise exposure and sleep disturbance.

NCT ID: NCT05035927 Active, not recruiting - Clinical trials for Binge Eating Disorder

Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

Start date: March 16, 2022
Phase: Phase 2
Study type: Interventional

To better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP 8802 among individuals with Binge Eating Disorder. This is a single-center phase 2a open-label study to assess the safety and feasibility of a single dose of TRP 8802 in subjects with BED. Subjects will undergo screening, preparation therapy sessions, dosing, integration therapy sessions, and follow-up for 12 weeks following the dose of TRP 8802. The total participation in the study will be up to approximately 5 months.

NCT ID: NCT05035836 Active, not recruiting - Breast Cancer Clinical Trials

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Start date: November 16, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined by pathologic complete response (pCR) .

NCT ID: NCT05035823 Active, not recruiting - Clinical trials for Spinal Cord Injuries

COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Start date: April 27, 2022
Phase: N/A
Study type: Interventional

The Synchron motor neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex. The purpose of this research is to evaluate safety and feasibility. The MNP is a type of implantable brain computer interface which bypasses dysfunctional motor neurons. The device is designed to restore the transmission of neural signal from the cerebral cortex utilized for neuromuscular control of digital devices, resulting in a successful execution of non-mechanical digital commands.

NCT ID: NCT05035667 Active, not recruiting - Clinical trials for Advanced Malignant Solid Neoplasm

Patient Considerations of Social Media Account Management After Death

Start date: December 22, 2020
Phase:
Study type: Observational

This study examines how supportive care clinic patients have made decisions or had discussions about how their caregivers or family should manage their social media account(s) after death. Collecting information on the use of social media and preferences will allow for a better understanding of patient's needs in the dying process and may identify populations in need of education, identify a possible source of anxiety and stress, and allow for an informed discussion of digital legacy.

NCT ID: NCT05035082 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

REALYSE
Start date: September 1, 2021
Phase: Phase 4
Study type: Interventional

This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the study is to see how well RYBELSUS® is at lowering blood sugar compared to other tablets when used in addition to metformin. Participants doctor will give participants either RYBELSUS® or any other blood sugar lowering tablets - which treatment participants get is decided by chance. The doctor treating participants diabetes will give participants a prescription for the medicine and tell how to take it. The study will last for about 1 year. Participants will have 2 planned visits with their doctor which are part of the usual routine diabetes management: the first visit is when participants are included in the study, the second visit is a 1-year follow-up visit. In addition, the study personnel will contact participants up to 3 times during this period and to follow-up on information from participant doctors visits. Participant will be asked to respond 3 times to 4 questionnaires via their personal smartphone or tablet or paper if participant do not have access to one during the study. All clinic visits are part of the usual routine diabetes management and are covered by participants health insurance plan. The study team will collect information from these visits recorded in the medical chart. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.